Long-term kinetics of anti-SARS-CoV-2 antibodies in a cohort of 197 hospitalized and non-hospitalized COVID-19 patients

Favresse, Julien; Elsen, Marc; Eucher, Christine; Laffineur, Kim; Eeckhoudt, Sandrine Van; Nicolas, Jean Baptiste; Gillot, Constant; Dogné, Jean Michel; Douxfils, Jonathan

doi:10.1515/cclm-2020-1736

Cited by 16 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may explain why the total and IgG antibodies declines are closer in the seropositive subgroup [ 27 , 28 ]. Interestingly, in seropositive subjects, the anti-NCP antibodies level did not significantly decline over at least day 180 [ 29 ]. Some groups have suggested that anti-NCP antibodies confer additional immunity in seropositive subjects but this is subject to debate in the literature [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers

et al. 2021

Self Cite

View full text Add to dashboard Cite

Data about the long-term duration of antibodies after SARS-CoV-2 vaccination are still scarce and are important to design vaccination strategies. In this study, 231 healthcare professionals received the two-dose regimen of BNT162b2. Of these, 158 were seronegative and 73 were seropositive at baseline. Samples were collected at several time points. The neutralizing antibodies (NAbs) and antibodies against the nucleocapsid and the spike protein of SARS-CoV-2 were measured. At day 180, a significant antibody decline was observed in seronegative (−55.4% with total antibody assay; −89.6% with IgG assay) and seropositive individuals (−74.8% with total antibody assay; −79.4% with IgG assay). The estimated half-life of IgG from the peak humoral response was 21 days (95% CI: 13–65) in seronegative and 53 days (95% CI: 40–79) in seropositive individuals. The estimated half-life of total antibodies was longer and ranged from 68 days (95% CI: 54–90) to 114 days (95% CI: 87–167) in seropositive and seronegative individuals, respectively. The decline of NAbs was more pronounced (−98.6%) and around 45% of the subjects tested were negative at day 180. Whether this decrease correlates with an equivalent drop in the clinical effectiveness against the virus would require appropriate clinical studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…We therefore confirm that the strongest correlations are observed using anti-S or anti-RBD assays [ 5 , 29 , 34 , 35 , 36 ] and our study highlights that correlations were especially high with the IgG assay. The fact that anti-NCP assays had a low correlation with the neutralizing activity was expected, as NAbs are directed against the S protein [ 37 ]. Nevertheless, it is important to keep in mind that a few patients may develop specific antibodies, i.e., antibodies detected by conventional serological assays, which do not translate into a detectable neutralizing activity.…”

Section: Discussionmentioning

confidence: 99%

Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2

Favresse

Gillot

Chiaro

et al. 2021

Viruses

Self Cite

View full text Add to dashboard Cite

The evaluation of the neutralizing capacity of anti-SARS-CoV-2 antibodies is important because they represent real protective immunity. In this study we aimed to measure and compare the neutralizing antibodies (NAbs) in COVID-19 patients and in vaccinated individuals. One-hundred and fifty long-term samples from 75 COVID-19 patients were analyzed with a surrogate virus neutralization test (sVNT) and compared to six different SARS-CoV-2 serology assays. The agreement between the sVNT and pseudovirus VNT (pVNT) results was found to be excellent (i.e., 97.2%). The NAb response was also assessed in 90 individuals who had received the complete dose regimen of BNT162b2. In COVID-19 patients, a stronger response was observed in moderate–severe versus mild patients (p-value = 0.0006). A slow decay in NAbs was noted in samples for up to 300 days after diagnosis, especially in moderate–severe patients (r = −0.35, p-value = 0.03). In the vaccinated population, 83.3% of COVID-19-naive individuals had positive NAbs 14 days after the first dose and all were positive 7 days after the second dose, i.e., at day 28. In previously infected individuals, all were already positive for NAbs at day 14. At each time point, a stronger response was observed for previously infected individuals (p-value < 0.05). The NAb response remained stable for up to 56 days in all participants. Vaccinated participants had significantly higher NAb titers compared to COVID patients. In previously infected vaccine recipients, one dose might be sufficient to generate sufficient neutralizing antibodies.

show abstract

“…27,28 Interestingly, in seropositive subjects, the anti-NCP antibodies level did not decline over at least day 180. 29 Some groups have suggested that anti-NCP antibodies confer additional immunity in seropositive subjects but this is subject to debate in the literature. 30 Besides, in our subgroup analysis, we did not identify a difference in terms of NAbs titers between seropositive and seronegative subjects (Table 1).…”

Section: Discussionmentioning

confidence: 99%

Waning of IgG, total and neutralizing antibodies 6 months post-vaccination with BNT162b2 in healthcare workers

Bayart

Douxfils

Gillot

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Data about the duration of humoral response following COVID-19 vaccines are mandatory to establish appropriate population vaccination strategy. This study reports on the antibody decline observed in a population of COVID-19 naïve and COVID-19 positive individuals having received the two dose regimen of the BNT162b2 vaccine. Six months after vaccination, a significant antibody decline was observed in both COVID-19 naïve and positive individuals. The estimated half-life of total and IgG antibodies differs and ranges from several months for total antibodies to only several weeks for IgG antibodies, explaining the significant proportions of participants with non-detectable levels of neutralizing antibodies at 6 months. Whether this decrease correlates with an equivalent drop in the clinical effectiveness against the virus will require appropriate clinical studies. Nevertheless, these data are already important to support the decision-making on the potential use of a booster dose.

show abstract

Long-term kinetics of anti-SARS-CoV-2 antibodies in a cohort of 197 hospitalized and non-hospitalized COVID-19 patients

Cited by 16 publications

References 32 publications

Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers

Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers

Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2

Waning of IgG, total and neutralizing antibodies 6 months post-vaccination with BNT162b2 in healthcare workers

Contact Info

Product

Resources

About